

**REPORT OF MEETING**



**WORLD HEALTH ORGANIZATION**



**SECRETARIAT OF THE PACIFIC  
COMMUNITY**

---

**INAUGURAL MEETING OF THE PPHSN PUBLIC HEALTH  
LABORATORY NETWORK**

(Noumea, New Caledonia, 19-20 April 2000)

---

Secretariat of the Pacific Community  
Noumea, New Caledonia  
2001

Note: the dates given are indicative, as the participants agreed they were not realistic, but didn't have the opportunity to further discuss them. All the dates need to be adapted according to the work commitments of the key players and to be flexible.

© Copyright Secretariat of the Pacific Community, 2001

All rights for commercial / for profit reproduction or translation, in any form, reserved. The SPC authorises the partial reproduction or translation of this material for scientific, educational or research purposes, provided that SPC and the source document are properly acknowledged. Permission to reproduce the document and/or translate in whole, in any form, whether for commercial / for profit or non-profit purposes, must be requested in writing. Original SPC artwork may not be altered or separately published without permission.

Original text: English

Secretariat of the Pacific Community Cataloguing-in-publication data

Inaugural meeting of the PPHSN Public Health Laboratory Network (19-20 April 2000 : Noumea, New Caledonia)

Report of Meeting

1. Public health - Oceania. 2. Medical laboratories - Oceania - Utilization.  
I. Title II. Secretariat of the Pacific Community III. Series

614.429

ISBN 982-203-812-7

ISSN 0377-452X

AACR2

Secretariat of the Pacific Community  
BP D5  
98848 Noumea Cedex  
New Caledonia

Telephone: +687 26 20 00

Facsimile: +687 26 38 18

E-mail: [spc@spc.int](mailto:spc@spc.int)

<http://www.spc.int>

Prepared for publication and printed at the  
Secretariat of the Pacific Community Headquarters,  
Noumea, New Caledonia, 2001

**TABLE OF CONTENTS**

	<b>Page</b>
I. AGENDA	1
II. OBJECTIVES OF THE MEETING	2
III. SUMMARY OF THE WORKING GROUPS	3
IV. LIST OF PARTICIPANTS	19
ANNEX 1 — WORKING GROUP B2 – INDICATIONS AND PROTOCOLS FOR SPECIMEN COLLECTION, STORAGE, AND TRANSPORT TO LEVEL 2 AND 3 LABORATORIES. PLAN OF ACTION	25
ANNEX 2 — LIST OF DOCUMENTS	27
ANNEX 3 — GUIDELINE FOR THE WORKING GROUPS	28



## I. AGENDA

### Wednesday 19 April 2000

- 8:00 Registration
- 8:15 Opening ceremony  
Election of chairpersons and drafting committee
- 9:00 Objective and expected outputs of the meeting
- 9/15 Coffee break
- 9:30 Self-introduction of the participants, with brief presentation of their facilities and activities
- 10:30 Background: - From PPHSN to PPHSN public health laboratory network  
- Existing CDs prevention and control strategies in the Pacific Island region  
- Summary of the findings from the laboratories assessment  
- Legal protection
- 11:15 Working groups:
1. Laboratories lists and contacts
  2. Target diseases for level 2 laboratories
- 12:00 Working groups presentations and plenary discussion / recommendations
- 12:30 Lunch break
- 13:30 Working groups:
1. List of tests  
List of equipment/reagents /disposable available/needed, and starting stocks and procurement procedures
  2. Indications and protocols for specimen collection, storage and transport to level 2 and 3 laboratories
  3. Roles of level 3 laboratories  
Quarantine services & airlines: specimen transport constraints & problems, and proposed solutions. Preparation of the telemeeting on quarantine issues
  4. Flow of information and communication, with plan of implementation
- 15:00 Tea break
- 15:15 Group work (continued)
- 16:30 Break — Drafting committee consolidates draft plan of action

### Thursday 20 April 2000

- 8:00 EWORS presentation
- 8:15 Working group presentations and plenary discussion / plan of operations
- 10:15 Coffee break
- 10:30 Telemeeting on quarantine issues
- 11:20 Working groups:
1. Human resources needs and solutions: staffing & training
  2. Funding mechanisms and overall coordination
  3. Quality control program
  4. Legal protection
- 13:00 Lunch break
- 13:30 Drafting committee consolidates draft plan of action
- 15:00 Working groups presentations only
- 15:45 Tea break
- 16:00 Plenary discussion: plan of action of last group works, overall plan of action. Summary of the meeting (with key issues)
- 17:00 Closing ceremony

## II. OBJECTIVES OF THE MEETING

Within the framework of the Pacific Public Health Surveillance Network, development of a plan of operation identifying needs and resources for the implementation of the public health laboratory Network in the Pacific Islands region.

### Expected Outputs (with existing/possible constraints for each output)

- List of laboratories involved in the PPHSN Public Health Laboratory Network, including the contact person(s) in each laboratory. Plan of action to have all these laboratories involved in the Network
- List of target communicable diseases for level 2 laboratories
- List of tests to be conducted (level 2 and level 3 laboratories) and specimen to be taken with practical comments on technical issues
- List of equipment/reagents/disposable materials available/needed by level of laboratory (specimen collection, storage, shipment, and testing) with starting stocks, procurement procedures
- Indications and protocols for specimen collection, storage and transport to level 2 and 3 laboratories
- Roles of level 3 laboratories clearly identified
- Legal protection:
  - Quarantine services and airlines and potential or existing transport problems/constraints listed. Plan for involving airlines and quarantine services through briefing + agreement, and solving the problems
  - Intellectual property problems and proposed solutions listed
- Flow of information and communication designed, with plan of implementation
- Human resources needs and possible solutions identified: staffing and training
- Funding mechanisms (initial & recurrent costs) envisaged
- Realistic quality control program
- Procedures for overall coordination and implementation of the plan of action

### III. SUMMARY OF THE WORKING GROUPS

#### WORKING GROUP A1 LABORATORIES LISTS AND CONTACTS

(Wednesday 19 April 2000, morning)

1. The first group recommendations is that all endeavours will be made to increase “recruitment” (response) from level 1 laboratories including private facilities if possible. In all cases this will be only if Pacific Island country/territory Governments will agree to such arrangements. The group recommended that e-mail communication means at level 1 laboratories (at least at the national level) will be strengthened and that the necessary support will be sought.
2. The group endorsed the list of the currently proposed level2 lab network. However a specific recommendations was made for New Zealand to decide and formerly indicate to PPHNS instances which facilities will precisely/namely be involved (e.g., ESR, PPTC<sup>2</sup>). Considering that the Malardé Institute is in a transitory phase complementary with New Zealand participation must be considered.
3. A list of criteria to be fulfilled for level 2 laboratories was discussed. Level 2 laboratories must:
  - ➔ have an acceptable<sup>3</sup> turn around of specimen to work on;
  - ➔ be able to cope with an increase of flow of specimen due to an outbreak situation (provided that specimen would have been appropriately selected beforehand);
  - ➔ willingness to participate and enhanced laboratory capability.
4. It was recalled that in the case of Guam some necessary improvement in the technical equipment was found necessary at the time of the on-site expertise carried out by the Pasteur Institute in late 99 specially for the diagnosis for influenza, dengue and measles.
5. Regarding Fiji, laboratory support in training, follow-up and advisory services, in order to enhance technical capacity, was similarly flagged out at the same time.

#### WORKING GROUP A2 TARGET DISEASES FOR LEVEL 2 LABORATORIES

(Wednesday 19 April, morning)

6. The working group decided that there should be two groups of priority diseases at level 2 laboratory.

##### First Target Diseases

- Measles (rubella)
- Dengue

##### Second target diseases

- Influenza
- Leptospirosis
- Cholera
- Typhoid

---

<sup>1</sup> Institute of Environmental Science and Research

<sup>2</sup> Pacific Paramedical Training Centre

<sup>3</sup> An acceptable turn around means that the necessary diagnosis techniques must be in use routinely, i.e., and not be re-started in the case of an outbreak occurrence.

7. The first group will be under surveillance and diagnostic procedures at level 2 laboratories at the inception of the network. Two issues were identified as per the immediate inclusion of the second group of diseases:

- Funding
- Technical/reagents/equipment

8. During the first 12-18 months of operations of the public health laboratory network activities will be monitored in order to find out solutions to cope with the two above mentioned issues.

9. In the interim the question was raised whether operational guidelines could be developed so that level 1 laboratories would know what to do with suspected cholera and typhoid outbreaks on one hand, and influenza and leptospirosis on the other hand (e.g., locally testing for cholera and typhoid and referring to level 3 laboratories for influenza and leptospirosis). It was decided that further working group discussions will resolve that question.

10. The group also recommends that the identified resource problem will be duly acknowledged in order to facilitate the quest for solutions.

11. The point was also raised that it might not be necessary requirements for all level 2 laboratories that they should be able to implement diagnostics facility for influenza and leptospirosis at the inception of the network.

12. It was also flagged out that diagnostic capacity building of level 2 labs should not happen at the expenses of the possibility of diagnosing/monitoring diseases of local importance.

13. It is to note that Acute Haemorrhagic Conjunctivitis (AHC) is not considered of being part of the list of diseases that level 2 laboratories will monitor in the near future (as such, AHC outbreaks will continue to possibly be monitored on PACNET, but will no longer be namely on the list of priority diseases targeted by PACNET).

**WORKING GROUP B1**  
**LIST OF TESTS FOR LEVEL 2 LABORATORIES**  
**LIST OF EQUIPMENT/REAGENT/DISPOSABLE AVAILABLE/NEEDED**  
**STARTING STOCKS AND PROCUREMENT PROCEDURES**  
(Wednesday 19 April, afternoon)

**Action points**

14. *The supplies required by level 2 laboratories are dependant on the methodologies to be used and the number of specimens likely to be received.*

15. **General requirements**

- e-mail facilities, (L1, L2 and L3 level labs)
- -80° C facilities including racks boxes/ boxes/serum storage vials
- ELISA facilities
- reagents (minimum stock requirements)

## 16. List of tests for level 1 and 2 laboratories

Disease	Laboratories level 1	Laboratories level 2
Measles/Rubella	(refer all samples to L2)	IgM ELISA
Typhoid	Routine (refer a sample of strains to L2)	Antibiotic resistance and QC
Vibrio	Routine (refer a sample of specimens to L2)	confirmation (serotyping) and QC
Influenza	(refer all samples to L2)	Immunofluorescence on nose-swabs ELISA on nose-swabs
Dengue (*)	(refer all samples to L2)	IgM ELISA HAI (paired serum) PCR (long term prospect)
Leptospirosis (**)	(refer all samples to L2)	ELISA MAT

(\*) For development of further testing capacity PCR is recommended over viral isolation.

- Setting of adequate premises and protocols for PCR would need to be rigorous
- PCR would give considerable additional capacity such as typing of influenza.

(\*\*) The problem needs to be quantified first (IPNC, lab in Brisbane)

### *Explanatory note*

- ELISA = enzyme-linked immunosorbent assay
- HAI = hemagglutination inhibition
- PCR = polymerase chain reaction
- MAT = micro-agglutination test (direct agglutination)
- IgM, IgG = immunoglobulin class M or G

## **Starting stocks and procurement procedures**

### **Stock**

17. Minimum stock needs to be held to enable immediate response/dispatch. The minimum level will depend on potential demand.

### **Procurement procedures**

18. This will depend on who is funding supplies and needs to be looked at further.

### **19. Recommendations**

- Measles/dengue minimum stock: 1 kit
- Establish good communication link by e-mail/fax to enable request of further reagents
- Supply of minimum stocks need to be staggered to avoid problems with expiry dates
- Review of laboratories who develop their own reagents/tests to ensure quality control of in-house reagents/tests.
- That these minimum stocks held are not for clinical services but for the public health surveillance.
- Funding mechanism needs to be discussed.
- Appoint a working group to investigate further.

### **Working Group**

20. To appoint a working group to define what is a suitable number of samples/methodologies per each disease.

21. It is difficult to predict what supplies/stocks are required a review after a period of time will be needed to readjust the laboratory supplies/minimum stocks.

22. Within the working group there is need of representation from epidemiologists and from L3, L2 and L1 labs.
- What are appropriate methodologies?
  - What number of samples are appropriate/expected?
  - What is the scope for collection of samples at the field level, how will this impact the L2 methodologies selected?
  - What is the potential for future PCR capacity at L2 ( particularly Guam, Fiji) including consideration of what is required to set adequate premises and rigorous protocols to prevent erroneous results?
23. Aim should be to present a range of choices/options that can be used accordingly to the individual countries needs and expectations.
24. It should be clearly identified what lab does what, and all the labs should be listed with this information in a document.

### **Laboratory Requirements for Dengue Diagnosis at Level 2 Laboratories- 3 points of view**

25. **First point of view**

- IgM ELISA is the most feasible testing procedure for laboratories in Fiji and Guam. Despite of non-specific reactions, IgM ELISA could be a useful method, if the proper sampling, interpretation and confirmation (level 3 laboratory) procedures are provided.
- A collection of paired sera for HAI test should also be promoted at same time. A clear laboratory guideline and quality control mechanism should be established for HAI test.
- An establishment of PCR for all level 2 laboratories should be planned as a long-term plan, including training.

26. **Second point of view**

- The strategy of detection of epidemics at level 2 laboratory must involve conventional serological methods (detection of total IgM using MAC-ELISA, detection of total Ig using HIA). In order to obtain a clear biological confirmation of cases, these methods require the collection of 2 samples 8-10 days apart in order to evidence significant increasing of antibodies.
- This protocol requires to be based on an efficient network of selected physicians in order to optimise the efficiency of surveillance (syndromic surveillance).
- The implication of level 3 laboratories (PCR and/or viral isolation) could be activated by level 2 laboratories in a case of acute and expanded epidemic situation in order to obtain as soon as possible the confirmation of the etiology.

27. **Third point of view**

- Single IgM ELISA result is not confirmatory but can be useful in the context of a suspected outbreak to enable a vigilant and appropriate public health response.
- Paired serum collection has been tried (& discussed) in the past and many practical issues have prevented a successful system from being established.
- To enable PRO-ACTIVE vigilant surveillance use of ELISA IgM on single samples ALONGSIDE encouragement for paired sera should be used. Level 2 labs should have ELISA IgM facilities for dengue & use discretion per its use when paired sera are not available.
- Insistence of paired sera (e.g. HAI confirmation of dengue) will limit the ability of some areas to obtain samples for referral to level 2 labs for dengue surveillance.
- Suggest use of IgM ELISA, HAI if paired sera available & referral of IgM positive samples for confirmation at level 3 (PCR testing).

**WORKING GROUP B2**  
**INDICATIONS AND PROTOCOLS FOR SPECIMEN COLLECTION, STORAGE, AND**  
**TRANSPORT TO LEVEL 2 AND 3 LABORATORIES**  
(Wednesday 19 April, afternoon)

**Plan of action**

**28. Indications for specimen collection**

*What?*

Guidelines for specimen collection (based on surveillance case definitions) for the 6 target diseases: when and what to collect.

*Who?*

PPHSN-CB, as part of the development of surveillance and response guidelines

*When?*

By November 2000

*Comments*

- Draw on existing guidelines and reference sources.
- Consider external monitoring of the demand for and appropriate use of public health laboratory services (e.g. by EpiNet)

**29. Shipping guidelines**

*What?*

Draft detailed guidelines for packing, labelling, and shipping specimens, including an assessment of likely demand.

*Who?*

A Network member if time available, but more likely by a consultant (x 1 month)

*When?*

Process underway by November 2000

*Comments*

- Draw on existing guidelines and reference sources.
- Incorporate communications methods to share information and track shipped specimens.
- Consider formalizing arrangements with selected transit hubs (e.g. Nadi, Brisbane).
- Consider outsourcing shipping arrangements to a private company.
- Incorporate feedback from recipient labs on adequacy of packing.

**30. Shipping supplies**

*What?*

Supplies for specimen collection and shipping provided to level 1 labs, and in larger quantities to selected central sites.

*Who?*

- “Prime” the system with supplies provided by WHO.
- Seek other support for maintenance supplies (e.g. recycling from L3 labs, donor or L3 lab contributions).

*When?*

Initial supplies provided by August 2000.

*Comments*

Incorporate an inventory system and an audit of utilisation, developed by PPHSNLabNet Working Group.

### 31. **Shipping arrangements**

*What?*

Convene meetings in Nadi and Guam with airline representatives, shipping agents, and representatives of airport services and customs to consider and resolve shipping requirements and storage in transit.

*Who?*

PPHSN-CB members convene Nadi meeting; seek support from Micronesia-based PPHSNLabNet members to convene Guam meeting.

*When?*

September 2000

*Comments*

- Draw on existing information sources for background on current IATA<sup>4</sup> and non-IATA requirements.
- Seek agreements for support.

### 32. **New technologies**

*What?*

- Explore other options for point of care (field) tests, and for specimen collection, such as filter paper methods, to reduce shipping complexity and cost.
- Assess cost benefit.

*Who?*

Seek interest and support from L3 reference laboratory staff.

*When?*

Ongoing.

### 33. **Indicator diseases**

*What?*

Incorporate a more common condition, such as (suspected) influenza, as soon as possible, with guidelines to allow its use as a continuing test of the system.

*Who?*

PPHSN LabNet

*When?*

As soon as possible.

---

<sup>4</sup> International Airlines and Transportation Association

### 34. **Training**

*What?*

Develop a training plan for country-level training of L1 staff in packing and shipping specimens.

*Who?*

Seek support from reference laboratories involved in training.

*When?*

November 2000

*Comments*

Such training may be incorporated into regularly scheduled visits for other laboratory training or quality assurance monitoring.

### 35. **Funding**

*What?*

Consider the funding implications as each of the above is developed, and incorporate this into overall PPHSN LabNet funding requirements.

*Who?*

Those responsible for each of the above.

The action plan of the workinggroup B2 is presented in a Table in Annex 1 pages 26 and 27

**WORKING GROUP B3  
ROLES OF LEVEL 3 LABORATORIES  
(Wednesday 19 April, afternoon)**

**Roles of Level-3 laboratories:**

Quality control  
PCR: molecular typing

Virulence studies  
Strain identification

36. Consideration needs to be given to communication networks and how the information will be disseminated in a timely relevant manner.

### 37. **Quality control**

- Could be achieved by expanding the RCPA & NRL in Australia to forward testing panel (quality control) to Pacific Island Nations – specifically level 2 labs.
- Consideration should also be given to introducing quality management procedures in place similar to NAZA + IS09001.

### 38. **PCR : molecular typing**

- Appropriateness of testing and rôle of specific laboratories (level 3) – laboratories guides.
- Minimum of two laboratories.

### 39. **Virulence studies**

Needs to be clearly defined and may have minimal impact (depending upon organism in question on Public Health impact).

40. **Strain identification**41. **Sending the samples: the problem of quarantine services & airlines**

- IATA<sup>5</sup> packaging critical to ensure entry of clinical samples into country.
- Cost of IATA packaging will need to be met by (see attached) some source. Packaging can be reused.
- Customs declaration forms must be appropriately filled out. «Diagnostic samples of no commercial value».
- Reputable courier company must be employed.
- Clear written guidelines need to be established for each “sending” laboratory and each “recipient” level 2 or 3 lab. Permits need to be in place, as well as there must be an advance notice that samples are being forwarded. A contact list is important.
- Level 2 labs should have access to either dry ice or liquid nitrogen as a prerequisite.
- SPC are going to homework hard with authorities to facilitate movements of samples to level-3 laboratories in appropriate condition.
- Education of all laboratory staff not only on proper method of forwarding samples to level-2 and level-3 lab, but also on the appropriateness of the testing requested.
- Personal telephone, email, or fax communication with referral lab prior to sending samples.

**WORKING GROUP B4  
FLOW OF INFORMATION AND COMMUNICATION, WITH PLAN OF  
IMPLEMENTATION**

(Wednesday 19 April, afternoon)

**Action Plan**

42. **Reach agreement regarding policies and procedures on the flow of information → MOA within PPHSN LabNet**

- information shared between labs to be coded in terms of patient identity;
- laboratories at different levels only share information within the PPHSN LabNet between authorized individuals;
- information within the PPHSN LabNet transmitted through most secure mechanism available, ideally through an encrypted server, alternatively by phone between authorized individuals;
- only recognized MOH authorities may release information outside of the PPHSN LabNet;
- MOH encouraged to define national policies & procedures re: flow of samples between labs within nation, flow of information within nation, release of information from MOH.


43. **Develop necessary infrastructure to support communication policies and procedures of the PPHSN LabNet**

- maintain PACNET-Lab for on-going discussion of developmental issues among an extended working group;
- establish PACNET-Restricted for verification of outbreaks;
- make available a secure server at SPC;
- develop customized website for the exchange of encrypted information within PPHSN LabNet;

---

<sup>5</sup> International Airlines and Transportation Association

- develop dynamic database that documents all website activity → provide system for monitoring/analysis of usage;
- establish QC system to trial/monitor/revise above system;
- upgrade capability of all PPHSN LabNet users to use above Internet-based system (dedicated equipment, sustainable access to the Internet, training, technical support).



= encrypted transmission via secure website

= standard email message on server

\* note: in the absence of Internet access, information shared by phone between author



- what training is currently available
  - canvas current membership
  - call for expectations of interest
    - current Pacific/Pacific Rim academic institutions and L3 laboratories
    - wider audience e.g. Japan
  - → identify deficiencies
  - develop new curriculum if necessary
  - train the trainer e.g. L2s train L1 laboratories
  - establish linkages for ongoing training programmes.

#### 49. **Continuing professional education**

- its significance relative to PPHSNLabNet needs to be clearly articulated within the Pacific
- cultural change that embraces ongoing training
- distance education
- internet based teaching modules (longer term objective as self directed learning)
- inclusion of laboratory staff in established continuing education activities e.g. Grand Rounds
- presentations by visiting staff e.g. L3 laboratories/QA programme
- debriefing process from outbreak investigations → inclusive of laboratory staff (laboratory member as part of outbreak response team)
- outbreaks/lessons learnt written-up and used for FETP
- must be undertaken at recognised institution.

#### 50. **Funding**

- economic analysis as part of TOR of mapping exercise
- ? cost recovery via paying for training modules
- creating an expectation of higher wage/ promotion following training
- real problem for administrators : may be linked to contracts/certification e.g. New Caledonia. Not necessarily true for the rest of the Pacific at present
- staff migration, need to keep training
- user created demand e.g. increase testing as expertise increases
- network asset e.g. new training module marketed and sold outside the network for cost recovery.

#### **Additional comments**

51. The L1 laboratory questionnaire was mainly technical in nature and didn't collect information on the existing level of expertise or training needs.

52. There is currently no post graduate training in the Pacific at a level available in Australia and New Zealand and this requires attention.

53. There is in-service training available in New Caledonia but there is no ready access to modular training as per Australia and New Zealand.

54. Targetted courses are preferable to meet the needs of the Pacific, especially modules that build on "on the experience" rather than formal academic qualifications.

55. PPTC<sup>8</sup> was invited to take on this role for PPHSNLabNet.

56. Laboratory technician training in Australia and New Zealand is in the form of a Bachelor of Medical Science and is not easily portable.

---

<sup>8</sup> Pacific Paramedical Training Centre

57. Training modules exist, however, the form of delivery needs to be tailored to suit the needs of the Pacific e.g. block course on specific laboratory methods (PCR, ELISA techniques).
58. PPTC Modular training courses can be made available subject to funding.

**WORKING GROUP C2**  
**FUNDING MECHANISMS AND OVERALL COORDINATION**  
 (Thursday 20 April 2000, morning)

**Plan of Action**

**Co-ordination**

59. There is a need for a flexible structure for the facilitation and coordination of the PPHSN LabNet development, at both administrative and technical level.
60. This will be done by a technical working body (TWB) which will include SPC, WHO and Institut Pasteur from New Caledonia (the latter in its capacity of providing resources, including technical expertise and sharing of workload). SPC, in its capacity of PPHSN-CB Focal Point, will have the responsibility of some of the administrative issues related to the TWB.
61. The PPHSN CB should officially recognise the TWB, who will then be answerable to the CB and the PPHSN core members.
62. As well, the TWB will communicate with the countries and territories through the laboratory technical focal point (to be identified).
63. As the PPHSN-CB can invite any allied body of the network to its meeting, it is recommended the lab representative to the TWB be invited to the next CB meetings when they will be dealing with PPHSN LabNet issues. As well, whenever the CB meeting is held in a country or territory of a level 2 laboratory, the representative from this lab will be invited as well.

**Funding**

64. The drafting committee of the Inaugural Meeting of the PPHSN Public Health Laboratory Network should consolidate the funding requirements identified throughout the meeting and from the reports of the various working groups.
65. The focal point of the PPHSN-CB should estimate the cost of each, place these in a proposed order of priority, and indicate which are already funded or likely to be funded, and by whom.
66. The focal point should circulate this summary by May 2000 to all members of the CB and to representatives of L2 and L3 laboratories, for comments and modifications, and for suggestions on possible sources of support.
67. All members of the CB (and PPHSN members and L2/L3 laboratories, if possible) should explore further funding options.

(In table format):

Activity	Responsible	Target date	Comments
Consolidate information on funding needs	<b>Drafting committee</b>	<b>20 April 2000</b>	<b>Drawing on meeting documents, discussions, and working group reports.</b>
Estimate costs and prioritise funding needs	<b>CB focal point</b>	<b>May 2000</b>	<b>Indicate for which of these funding is assured or likely.</b>
Circulate summary to CB members and L2/ L3 laboratory representatives	<b>CB focal point</b>	<b>May 2000</b>	
Explore funding options	<b>CB, and all members of the PPHSN and PPHSN LabNet</b>	<b>Ongoing</b>	

**WORKING GROUP C3  
QUALITY CONTROL PROGRAMME**  
(Thursday 20 April 2000, morning)

**Plan of Action**

**68. Internal Quality Control**

a) Standardised Operational Procedures (SOP)

- SOP should be prepared at level 2 laboratories for all target diseases
- SOP should include procedures for internal quality control.
- The mechanism to share SOPs among laboratories should be established

b) Panel of samples

- Level 3 laboratories should provide panels of samples (sera for dengue and measles, slides for influenza).
- PPTC will be responsible for distribution of panels to level 2 laboratories

c) External Quality Control

- External quality control programme should be developed as a long-term plan.
- Existing quality control network should be utilized (Australian, USA, French)
- The funding mechanism should be established to implement External Quality Control programme
- PPTC will take a coordinating role in External Quality Control programme.

**69. Quality Control Strategy for each disease**

- Cholera / Typhoid: existing PPTC network for both level 1 and level 2 laboratories (expansion to other areas – funding)
- Dengue / Measles (Rubella): Serum Panel
- Influenza: Slide Panel
- Leptospirosis: to be decided

70. **Communication**

- The communication mechanism should be established to facilitate quality control programme (Website, email: PPHSN LabNet).
- Annual Meeting of laboratories would be useful to exchange information and improve the quality control system.

71. **Funding Requirements**

- Short-term
  - (1) Distribution of panels
- Long-term
  - (1) Expansion of PPTC Network (cholera / typhoid)
  - (2) External Quality Control
  - (3) Annual Meeting

**WORKING GROUP C4  
AIRLINES AND QUARANTINE  
(Thursday 20 April 2000, morning)**

**Plan of Action**

72. The group basically endorsed the two-leg strategy put forward during the teleconference and previous group work (Group B3).

- a) That the meeting incorporates in the final report :
- a list of all potential issues and problems related with transport (import and export) of biological specimen within the PPHSN laboratory Network, and
  - a recommendation that these will be passed to the Pacific Plant Protection Organisation SPC via the SPC Plant Protection Project which serves as the Secretariat of the PPPO Executive Body.
- b) That the PPHSN approaches Airlines, Quarantine and Health authorities in Fiji and Guam especially, with the help, in Fiji, of the SPC Plant Protection Project in order to:
- inform them of the PPHSN LabNet goals and Plan of action, and to discuss the ways of reaching potential agreements for these two critical regional transportation hubs
  - raise awareness about and discuss the problems of the smooth circulation of biological samples (human, vegetal and animal) throughout the PICTs.

73. In Fiji, the SPC PPProject should be the leading player, in first instance, in contacting the national Quarantine authorities.

74. In both meetings, the PPHSN should be primarily represented by appropriate CB members and/or by the CB Focal Point, when necessary.

75. The PPHSN should issue "Universal precautions" guidelines to specify how human samples should be handled and packaged in outbreak investigation circumstances, together with relevant monitoring procedures to ensure that these will be standard practices within the PPHSN LabNet. These guidelines and procedures will also encompass (and guarantee) that, in case of a potentially severe outbreak (according to clinical and epidemiological evidences) caused by an harmful emerging or already known pathogen, operational steps will be described for collecting, packaging, and shipping samples, and that the appropriate high security (P4) laboratory will be contacted. Level 2 labs will, in that case, not be involved in the diagnostic process, and be skipped over. These guidelines will also be passed over to PPPO for their information, comments and appreciation.

76. The PPHSN-CB will make an inventory of the Airline companies in the region and will determine those not being a member of the International Airlines and Transportation Association (IATA). The latter will then be approached in order to find out what are their specific requirements re. transportation of biological samples (e.g., if allowing biological samples to travel in the same plane as food stuff for sale). Further steps will be to explore the possibility of developing specific agreements within the umbrella of the PPHSN.

### **Intellectual Property**

77. That the case of any technology derived from outbreak investigations and other epidemiological studies (e.g., vaccines, scientific papers, germs identification, etc.) will be dealt separately under the currently existing copyright and other international agreements (refer to WIPO, UNESCO, Bio-diversity convention, etc.).

78. As for the issues of using biological samples for other studies than the original purpose for which they were taken—falling under a mix of “intellectual and community property” in the Pacific, the group recommends that, in any case, final approval on the matter is left to each individual Pacific Islands country and territory, according to the existing local legislation and code of ethics.

79. It is recommended that the PPHSN-CB consults with the individual PPHSN countries and territories about their individual requirements for informed consent.

80. The group also felt that a generic “informed consent” form will be developed for consideration by the PPHSN country-members, which will give individuals the choice of agreeing or not to the fact that the samples taken from them may be used for a different purpose later on. Once agreed on the content and endorsed by the PICTs, such a form could be placed on the PPHSN web-site, and be available for download by any national health authority, for example.

81. The group recommends that the PPHSN-CB develops, a code of conduct to be approved by the PPHSN Core members. This code will be of a particular interest for those samples collected during outbreak investigation, where the emergency context avoids having the necessary time to develop more specific contracts or Memorandum of Agreement<sup>9</sup> between the country/territory and the investigating agency/University/laboratory. If not in an emergency situation, these latter should be developed on an case by case basis, at country/territory level.

82. In drafting the above-mentioned PPHSN code of conduct, two background relevant experiences will be explored:

- the recent Nipah/Hendra virus outbreak that took place in Malaysia in 1999/2000, and
- the procedures developed within the International Network of Pasteur Institutes

---

<sup>9</sup> MOAs recommended by all working groups should be included into one unique MOA.

#### IV. LIST OF PARTICIPANTS

##### TEMPORARY ADVISERS

##### **Australia**

Dr Jennifer Leydon  
 Victorian Infection Diseases Reference Laboratory  
 (VIDR) Melbourne  
 10 Wreckyn Street  
 North Melbourne 3051  
 VICTORIA  
 Phone: (61) 3 9342 2647  
 Fax: (61) 3 9342 2676  
 E-mail: [jennie.leydon@nwhcn.org.au](mailto:jennie.leydon@nwhcn.org.au)

Dr Greg Smith  
 Scientific Manager (virology)  
 Queensland Health Scientific Services  
 39 Kessels Road, Cooper Plains  
 QUEENSLAND 4108  
 Phone: (61) 7 3274 9151  
 Fax: (61) 7 3274 9074  
 E-mail: [greg\\_smith@health.qld.gov.au](mailto:greg_smith@health.qld.gov.au)

##### **Fiji Islands**

Dr Joe Koroivueta  
 Consultant Virologist  
 Mataika House  
 Tamavua Hospital Complex  
 SUVA — FIJI  
 Phone : (679) 321 066  
 Fax : (679) 320 344  
 E-mail : [joekv@is.com.fj](mailto:joekv@is.com.fj)

Dr Mosese Seru  
 Research Assistant  
 Mataika House  
 Tamavua Hospital Complex  
 SUVA — FIJI  
 Phone: (679) 320 066  
 Fax: (679) 320 344

##### **French Polynesia**

Dr Regis Goursaud  
 Directeur du LABM  
 Institut Louis Malardé  
 B.P. 30  
 98713 PAPEETE — TAHITI  
 Phone: (689) 41 64 64  
 Fax: (689) 43 15 90  
 E-mail: [rgoursaud@malarde.pf](mailto:rgoursaud@malarde.pf)

**Guam**

Mr Severino David  
 Administrator  
 Bureau of Professional Support Services  
 Dpt of Public Health and Social Services (DPHSS)  
 PO Box 2816  
 HAGATNA 96932  
 Phone : (671) 735 7283/7289  
 Fax : (671) 734 2066  
 E-mail : [sdavid@mail.gov.gu](mailto:sdavid@mail.gov.gu)

**New Caledonia**

Dr Philippe Pérolat  
 Director  
 Institute Pasteur of New Caledonia  
 B.P. 61  
 98845 NOUMÉA Cedex  
 Phone : (687) 27 26 66  
 Fax : (687) 27 33 90  
 Mobile : (687) 78 25 85  
 E-mail : [perolat.pasteur@canl.nc](mailto:perolat.pasteur@canl.nc)

**New Zealand**

Dr Diana Martin  
 Institute of Environmental  
 Science and Research (ESR)  
 PO Box 50348  
 Kenepuru Drive  
 PORIRUA  
 Phone : (64) 4 914 0700  
 Fax : (64) 4 914 0770  
 E-mail : [Diana.Martin@esr.cri.nz](mailto:Diana.Martin@esr.cri.nz)

**OBSERVERS****AusAID**

Dr Jeffrey Hii  
 Health Adviser  
 AUSAID  
 GPO Box 887  
 CANBERRA ACT 2601  
 Phone : (61) 2 6206 4947  
 Fax : (61) 2 6206 4870  
 E-mail : [jeffrey\\_hii@ausaid.gov.au](mailto:jeffrey_hii@ausaid.gov.au)

**Centers for Disease Control**

Mr Peter Crippen  
 CDC Public Health Adviser  
 Department of Health, Education and Social Affairs  
 PO BOX PS70  
 96941 Palikir, POHNPEI  
 Federated States of Micronesia  
 Phone : (691) 320 2619  
 Fax : (691) 320 5263  
 E-mail : [crippen@mail.fm](mailto:crippen@mail.fm)

**Pacific Paramedical Training Centre**

Dr John Elliot  
 Medical Laboratory Technologist/Microbiologist  
 Pacific Paramedical Training Centre  
 PO Box 7013  
 WELLINGTON  
 New Zealand  
 Phone: (64) 4 389 6295  
 Fax:  
 E-mail: [pptc@clear.net.nz](mailto:pptc@clear.net.nz)

**DoD-GEIS / US NAMRU 2**

Dr Kevin Porter  
 MC, USNR  
 Director  
 Viral Diseases Program  
 US NAMRU 2  
 JAKARTA  
 Indonesia  
 Phone: (62) 21 421 4457, ext: 4463  
 Fax: (62) 21 424 4507  
 E-mail: [porterkr@namru2.com](mailto:porterkr@namru2.com)

**COORDINATING BODY MEMBERS****Federated States of Micronesia**

Mr Amato Elymore  
 Health Statistician  
 Department of Health Services  
 P.O. Box PS 70  
 FSM National Government  
 Palikir, POHNPEI 96941  
 Federated States of Micronesia  
 Phone : (691) 320 2629  
 Fax : (691) 320 5263  
 E-mail : [fsmhealth@mail.fm](mailto:fsmhealth@mail.fm)

**Fiji Islands**

Dr Lepani Waqatakirewa  
 Acting Director Primary &  
 Preventive Health Services  
 Ministry of Health  
 Box 2223  
 Government Buildings  
 SUVA — Fiji  
 Phone : (679) 306 177  
 Fax : (679) 306 163  
 E-mail: [lwaqatakirewa@govnet.gov.fj](mailto:lwaqatakirewa@govnet.gov.fj)

**New Caledonia**

Dr Alain Swetschkin  
 Directeur  
 Direction des Affaires Sanitaires Sociales  
 98846 NOUMEA Cedex  
 Phone : (687) 24 37 01  
 Fax : (687) 24 37 02  
 E-mail: [dtass@gouv.nc](mailto:dtass@gouv.nc)

**Samoa**

Mrs Leilani Matalavea  
 TI Director  
 Department of Health Resource Planning  
 Information Research & development Division  
 Private Bag  
 APIA  
 Phone : (685) 21212  
 Fax : (685) 21440  
 E-mail : [leilani@samoa.net.ws](mailto:leilani@samoa.net.ws)

**Solomon Islands**

Mr Peter Wilikai Waleualo  
 Chief Medical Statistician  
 Statistician, Planning Unit  
 Ministry of Health & Medical Services  
 P.O. Box 349  
 HONIARA  
 Phone : (677) 23402/23403  
 Fax : (677) 20085  
 E-mail : [cchp@welkam.solomon.com.sb](mailto:cchp@welkam.solomon.com.sb)

**COORDINATING BODY ALLIED MEMBERS**

**Communicable Disease Network  
 Australia/New Zealand  
 And Population Health (ANU)**

Dr Angela Merianos  
 Director  
 Surveillance and Management Section  
 Communicable Diseases & Environmental Health  
 Branch  
 Population Health Division of the Commonwealth  
 Department of Health and Aged Care Australia  
 Phone: (61) 2 6289 8403  
 Fax: (61) 2 6289 8098  
 E-mail: [Angela.Merianos@health.gov.au](mailto:Angela.Merianos@health.gov.au)

**Fiji School of Medicine**

Dr Jan Pryor  
 Research Coordinator/MBBS  
 Curriculum Co-coordinator  
 Fiji School of Medicine  
 Co-coordinator, Western Pacific HealthNet  
 Private Mail Bag  
 SUVA — FIJI  
 Phone : (679) 311 700, ext. 1202/304 273  
 Fax : (679) 305 781  
 E-mail : [pryor@fsm.ac.fj](mailto:pryor@fsm.ac.fj)

**UNICEF**

Dr Arnold Calo-Oy  
 Immunisation Specialist  
 UNICEF Pacific Office  
 Private Mail Bag  
 SUVA — FIJI  
 Phone : (679) 300 439  
 Fax : (679) 301 667  
 E-mail : [calooya@unicef.org](mailto:calooya@unicef.org)

**SECRETARIAT****World Health Organization**

Dr Hitoshi Oshitani  
 Regional Adviser in Communicable Diseases  
 Western Pacific Regional Office  
 United Nations Avenue  
 PO Box 2932  
 MANILA  
 Philippines  
 Phone : (632) 528 8001/528 9964 direct line  
 Fax : (632) 521 1036  
 E-mail : [oshitanih@who.org.ph](mailto:oshitanih@who.org.ph)

Dr Michael O'Leary  
 Medical Officer  
 WHO Office for the South Pacific  
 PO Box 113  
 SUVA — Fiji  
 Phone: (679) 304 600  
 Fax: (679) 300 462  
 E-mail: [olearym@who.org.fj](mailto:olearym@who.org.fj)

Ms Reiko Muto  
 Associate Professional Officer  
 Communicable Diseases Prevention and Control  
 WHO Office for the South Pacific  
 PO Box 113  
 SUVA — Fiji  
 Phone : (679) 304 600  
 Fax : (679) 300 462  
 E-mail : [mutor@who.org.fj](mailto:mutor@who.org.fj)

**Secretariat of the Pacific Community**

Dr Yvan Souares  
 Epidemiologist  
 B.P. D5 — 98848 NOUMEA cedex  
 Phone : (687) 26 01 43  
 Fax : (687) 26 38 18  
 E-mail : [yvans@spc.int](mailto:yvans@spc.int)

Dr Tom Kiedrzynski  
 Notifiable Disease Specialist  
 B.P. D5 — 98848 NOUMEA cedex  
 Phone : (687) 26 20 00, Ext. 232  
 Fax : (687) 26 38 18  
 E-mail: [tomk@spc.int](mailto:tomk@spc.int)

Mrs Hazel Clothier  
Regional Laboratory Scientist  
PMB  
SUVA — Fiji  
Phone: (679) 321 154 – direct  
Fax: (679) 322 714  
E-mail: [hazelc@spc.int](mailto:hazelc@spc.int)

Mrs Elise Benyon  
Data Processing Officer  
B.P. D5 — 98848 NOUMEA cedex  
Phone : (687) 26 01 64  
Fax : (687) 26 38 18  
E-mail: [eliseb@spc.int](mailto:eliseb@spc.int)

Ms Mina Vilayleck  
Surveillance Information Officer  
B.P. D5 — 98848 NOUMEA cedex  
Phone : (687) 26 0181  
Fax: (687) 26 38 18  
E-mail: [minav@spc.int](mailto:minav@spc.int)

Ms Ginette Soehadi  
Project Assistant  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 20 00, Ext. 238  
Fax: (687) 26 38 18  
E-mail: [ginettes@spc.int](mailto:ginettes@spc.int)

Mr Phill Hardstaff  
Senior support engineer  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 01 41  
Fax: (687) 26 38 18  
e-mail: [philh@spc.int](mailto:philh@spc.int)

Mr Roy Benyon  
Interpreter  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 01 29  
Fax: (687) 26 38 18  
E-mail: [royb@spc.int](mailto:royb@spc.int)

Mrs Marie Bayle  
Interpreter  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 01 75  
Fax: (687) 26 20 00  
Email: [marieb@spc.int](mailto:marieb@spc.int)

Mrs Catherine Becour  
Translator  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 01 77  
Fax: (687) 26 38 18  
E-mail: [catherineb@spc.int](mailto:catherineb@spc.int)

Ms Karine Dreyfus  
Interpreter/  
B.P. D5 — 98848 NOUMEA cedex  
Phone: (687) 26 20 00  
Fax: (687) 26 38 18  
E-mail: [karined@spc.int](mailto:karined@spc.int)

**WORKING GROUP B2: INDICATIONS AND PROTOCOLS FOR SPECIMEN COLLECTION, STORAGE AND 3 LABORATORIES PLAN OF ACTION**

<b>Activity</b>	<b>Responsible</b>	<b>Target date</b>	<b>Comments</b>
<p><b>Indications for specimen collection</b></p> <p>Guidelines for specimen collection (based on surveillance case definitions) for the 6 target diseases: when and what to collect.</p>	PPHSN-CB, as part of the development of surveillance and response guidelines	November 2000	<ul style="list-style-type: none"> <li>♣ Draw on existing guidelines and reference sources.</li> <li>♣ Consider external monitoring of the for and appropriate use of public health laboratory services (e.g. by EpiNet)</li> </ul>
<p><b>Shipping guidelines</b></p> <p>Draft detailed guidelines for packing, labelling, and shipping specimens, including an assessment of likely demand.</p>	A Network member if time available, but more likely by a consultant (x 1 month)	Process underway by November 2000	<ul style="list-style-type: none"> <li>♣ Draw on existing guidelines and reference sources.</li> <li>♣ Incorporate communications method information and track shipped specimens</li> <li>♣ Consider formalising arrangements with selected transit hubs (e.g. Nadi, Brisbane)</li> <li>♣ Consider outsourcing shipping arrangements to a private company.</li> <li>♣ Incorporate feedback from recipient adequacy of packing.</li> </ul>
<p><b>Shipping supplies</b></p> <p>Supplies for specimen collection and shipping provided to level 1 labs, and in larger quantities to selected central sites.</p>	<ul style="list-style-type: none"> <li>♣ "Prime" the system with supplies provided by WHO.</li> <li>♣ Seek other support for maintenance supplies (e.g. recycling from L3 labs, donor or L3 lab contributions).</li> </ul>	Initial supplies provided by August 2000.	<ul style="list-style-type: none"> <li>♣ Incorporate an inventory system and of utilisation, developed by LabNet Working Group.</li> </ul>
<p><b>Shipping arrangements</b></p> <p>Convene meetings in Nadi and Guam with airline representatives, shipping agents, and representatives of airport services and customs to consider and resolve shipping requirements and storage in transit.</p>	<ul style="list-style-type: none"> <li>♣ PPHSN-CB members convene Nadi meeting.</li> <li>♣ Seek support from Micronesia-based LabNet members to convene Guam meeting.</li> </ul>	September 2000	<ul style="list-style-type: none"> <li>♣ Draw on existing information source background on current IATA and non-requirements.</li> <li>♣ Seek agreements for support.</li> </ul>

Activity	Responsible	Target date	Comments
<p><b>Indicator diseases</b></p> <p>Incorporate a more common condition, such as (suspected) influenza, as soon as possible, with guidelines to allow its use as a continuing test of the system.</p>	LabNet	As soon as possible	
<p><b>New technologies</b></p> <ul style="list-style-type: none"> <li>♣ Explore other options for point of care (field) tests, and for specimen collection, such as filter paper methods, to reduce shipping complexity and cost.</li> <li>♣ Assess cost benefit.</li> </ul>	Seek interest and support from L3 reference laboratory staff	Ongoing	
<p><b>Training</b></p> <p>Develop a training plan for country-level training of L1 staff in packing and shipping specimens.</p>	Seek support from reference laboratories involved in training.	November 2000	♣ Such training may be incorporated in regularly-scheduled visits for other lab training or quality assurance monitorin
<p><b>Funding</b></p> <p>Consider the funding implications as each of the above is developed, and incorporate this into overall LabNet funding requirements.</p>	Those responsible for each of the above		

## LIST OF DOCUMENTS

### Provisional Agenda

Informal 1 :	Objectives of the meeting
Informal 2 :	List of participants
Informal 3 :	List of documents
Informal 4 :	Guidelines for the working groups

### Working Papers :

Working paper 1 :	The Louis Malardé Institute Medical Biology Laboratory (LABM), Paper presented by Dr R. Goursaud, Malardé Institute, French Polynesia
Working paper 2 :	Guam Public Health Laboratory, Paper presented by Mr Severino David, Department of Health, Guam
Working paper 3 :	About ESR, Paper presented by Dr Diana Martin, ESR, New Zealand
Working Paper 4 :	Pacific Laboratory Network, Paper presented by Dr Philippe Pérolat, Pasteur Institute, New Caledonia

### Information Papers :

Information paper 1 :	EWORS – Early Warning Outbreak Recognition System, Dr Maudi Putri
Information Paper 2 :	Naval Medical Research Unit #2, Jakarta, Indonesia, Dr Kevin Porter
Information Paper 3 :	Pacific Paramedical Training Centre Profile, Dr John Elliot, PPTC, New Zealand

### Reference papers :

- WHO Recommended Surveillance Standards, Second Edition – October 1999.
- Report of Conference: PACNET/WESTERN PACIFIC HEALTHNet (WPHNet) Pacific Telehealth Conference, Noumea, New Caledonia, 30 November to 3 December 1998.

## **GUIDELINES FOR THE WORKING GROUPS**

This document is designed to provide all participants with clarification on the working group sessions. It explains the link between these sessions and the expected outputs of the meeting, and defines the role of the working group facilitator and rapporteur.

Should you need further details, please feel free to contact the meeting secretariat.

### **⌘ Purpose and expected outputs of the group works**

The goal of each group work (and of the meeting) is very practical: for each subject, it is to identify the operational steps to be achieved in order to get the PPHSN Lab Network operational, what means to come up with a realistic plan of action.

The plan of action must also identify the resources needed and available for its implementation.

The tasks to be performed by each working group in respect of one each of the topics addressed will be to:

- First clarify if necessary the different areas of the topic to be discussed, and what has to be covered by the plan of action.
- List the operational and practical steps to be taken and the activities to be carried out over the next 12-18 months (to be decided) in order, for example, to solve the (potential) problems with quarantine services and airlines.
- Identify the resources needed and available for achieving these steps and activities so that the PPHSN Lab Network becomes operational.

### **⌘ Composition of the working groups**

Each working group will have 1 facilitator and 1 rapporteur.

The facilitators are proposed by the organisers and selected at the beginning of the meeting.

As each rapporteur is part of the drafting committee, the rapporteurs are also selected at the beginning of the meeting.

### **⌘ Role of the facilitator**

The role of the facilitator will be to :

- facilitate the discussions, i.e. to initiate active and constructive interaction between the working group members.
- guide the discussions so that they result in practical recommendations (first morning) and a plan of action (all group works).
- help the rapporteur to wrap up the plan of action at the end of the session.

Note that the facilitator should be relieved of taking notes during the discussions. He/she will be assisted by the rapporteur.

### ⌘ Role of the rapporteur

In addition to being a working group member, the rapporteur will primarily concentrate on taking the minutes of the discussions, in a “plan-of-action” kind of format, i.e. as simple and clear as possible (limiting the editing).

The rapporteur will also be a key-person in the expected flow of information (see hereunder).

### ⌘ Presentation of group work

One person of each of the working groups (the facilitator, the rapporteur or someone else, as decided by the group) will also have to report to the meeting in plenary. He/she will:

- briefly summarise the contents of the discussions
- present the draft plan of action, as suggested by the participants to the group work

The meeting will then be able to further discuss these points during the plenary sessions.

### ⌘ The expected flow of information

As already mentioned above, the plan of action of each working group will be based on the minutes taken by the working group’s rapporteur. Drafting and editing will be done by him/her, with the help of the facilitator and any other volunteering member of the working group (keeping this drafting group to 2-3 people seems to be reasonable). The rapporteur will finalise his/her work in the drafting committee.

On Wednesday morning, the rapporteurs will wrap up and give their final draft recommendations/plan of action to the meeting secretariat contact person after the presentation and discussion in plenary session, with all the changes requested and approved during the plenary session included in the draft.

Regarding the other working group sessions (Wednesday afternoon and Thursday morning), the rapporteurs will have to wrap up the plan of action and pass it to the meeting secretariat contact person **right after the group works** During the plenary sessions, they will also be responsible of taking notes of the changes to be done in the plan of action they have drafted, and to communicate these changes to the meeting secretariat contact person

**The meeting secretariat contact person is Mrs Elise Benyon.**

Secretarial assistance will also be available for final formatting of the document and liaison with the translation services.